[Effect of estradiol dipropionate in various doses on induced uterine sarcomagenesis in mice].
Uterine sarcomas in (CBA X C57B1)F1 mice receiving 1,2-dimethylhydrazine (DMH) developed in 20% of animals. Concomitant administration of estradiol-dipropionate (EP) in doses of 2, 10 and 30 micrograms/mouse significantly increased tumour incidence up to 46.9, 62.5, and 50%, respectively, and shortened their latency: 42.3 weeks in a group receiving DMH alone and 36.7, 38.4 and 30.5 weeks in groups receiving DMH plus 2, 10 or 30 micrograms EP, respectively.
D019813:1,2-Dimethylhydrazine; D000818:Animals; D004127:Dimethylhydrazines; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D004958:Estradiol / Q000008:administration & dosage / Q000031:analogs & derivatives*; D005260:Female; D051379:Mice; D008810:Mice, Inbred C57BL; D008808:Mice, Inbred CBA; D012513:Sarcoma, Experimental / Q000139:chemically induced* / Q000453:epidemiology; D013997:Time Factors; D014594:Uterine Neoplasms / Q000139:chemically induced* / Q000453:epidemiology
D004127:Dimethylhydrazines; D004958:Estradiol; D019813:1,2-Dimethylhydrazine; C023482:estradiol dipropionate
Vliianie éstradiola dipropionata v razlichnykh dozakh na indutsirovannyĭ sarkomogenez matki u mysheĭ.